Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of εPA44 therapeutic hepatitis B vaccine
ChiCTR-TRC-11001496Phase 4Completed
- Sponsor
- Peking University First Hospital
- Start
- Dec 2003
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of εPA44, interferon gamma-1b and sargramostim in Chronic Hepatitis B (CHB) (4 arms), sponsored by Peking University First Hospital. Primary endpoints: Safety indicators, Virological response and 1 more. Started Dec 2003; status: completed.
02
Drugs
εPA44interferon gamma-1bsargramostim
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-TRC-11001496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001496.